Immunotherapy in asthma /
Saved in:
| Imprint: | New York, NY : M. Dekker, c1999. |
|---|---|
| Description: | xxvii, 669 p. : ill. ; 24 cm. |
| Language: | English |
| Series: | Lung biology in health and disease. v. 136 |
| Subject: | |
| Format: | Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/4023881 |
Table of Contents:
- Introduction
- Preface
- Contributors
- Part 1. Mechanisms of Allergic Asthma
- 1.. Human T Helper Type 1 and Type 2 Subsets
- I.. Introduction
- II.. Role of Cytokines in the Differentiation of Th1 and Th2 Helper Subsets
- III.. Effect of Antigen Concentration of Th Differentiation
- IV.. Effect of Different Costimulatory Molecules
- V.. Stability of Differentiated T Subpopulations
- VI.. Phenotypic Differences Between Th1 and Th2 Populations
- VII.. The Subsets in Disease
- VIII.. Conclusions
- References
- 2.. Mechanisms of Allergic Asthma: A Th2 Disease
- I.. Introduction
- II.. T-Cell Activation in Asthma
- III.. Immunoglobulin E Regulation
- IV.. T-Cell Cytokine Production in Asthma
- V.. Non-T-Cell Cytokines in Asthma
- VI.. Nonatopic ("Intrinsic") Asthma
- VII.. Glucocorticoid Resistance in Asthma
- VIII.. Cyclosporine
- IX.. Animal Models
- X.. Determinants of the Th2 Response in Asthma
- XI.. Chemokines in Asthma
- XII.. Conclusions
- References
- 3.. Mechanisms of Asthma: Asthma Is an Allergic Disease
- I.. Introduction
- II.. Epidemiology
- III.. Characteristics of the Allergic Immune Response and Its Relationship to Asthma
- IV.. Indoor and Perennial Allergens
- V.. Experimental Studies
- VI.. Treatment
- VII.. Conclusions
- References
- 4.. Inflammation and Airway Remodeling in Asthma
- I.. Introduction
- II.. Origin and Site of Inflammatory Cells in the Airways
- III.. Epithelium
- IV.. Submucosal Infiltrate
- V.. Importance of Inflammation in Asthma
- VI.. Airway Remodeling
- VII.. Conclusions
- References
- 5.. The Prognosis and Natural History of Asthma
- I.. Introduction
- II.. Asthma Symptoms
- III.. Factors Affecting the Outcome or Onset of Asthma
- IV.. Conclusion
- References
- Part 2. Allergen-Specific Immunotherapy
- Current Knowledge
- 6.. Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases (WHO Position Paper, Executive Summary)
- I.. Introduction
- II.. Allergen Standardization
- III.. Mechanisms
- IV.. Subcutaneous Immunotherapy
- V.. Other Routes of Immunotherapy
- VI.. Future Vaccines
- VII.. Research Needs
- References
- 7.. Allergen-Specific Immunotherapy: New Strategies Using Recombinant Allergens
- I.. Introduction
- II.. Molecular Biology of Indoor Allergens
- III.. New Strategies for Immunotherapy
- IV.. Conclusions
- References
- 8.. Elimination of Allergens
- I.. Introduction
- II.. Dust Mites
- III.. Animals
- IV.. Fungal Allergens
- V.. Other Allergens
- VI.. Conclusion
- References
- 9.. Standardization of Allergens
- I.. Introduction
- II.. Control of Allergen Extracts
- III.. Units of Standardized Extracts
- IV.. Standardized Extracts
- V.. Allergen Nomenclature
- References
- 10.. Allergen-Specific Immunotherapy: Past and Present
- I.. Introduction
- II.. Clinical Changes
- III.. Immunological Changes
- IV.. Studies with Specific Allergens
- V.. Problem Areas
- VI.. Untoward Reactions
- VII.. Depot Methods
- VIII.. Cross-Linked or Polymerized Antigens
- IX.. How Long to Continue Immunotherapy?
- X.. Standardization of Allergens
- XI.. Optimum Doses
- XII.. Dosage Programs
- References
- 11.. Allergen-Specific Immunotherapy: Mechanisms of Immunotherapy
- I.. Introduction
- II.. Serum Antibody Concentrations
- III.. Effector Cells
- IV.. Lymphocyte Response
- References
- 12.. Objectives of Immunotherapy in Asthma
- I.. Background
- II.. Appropriate Subject Selection and Endpoints
- III.. Conclusions
- References
- 13.. Allergen-Specific Immunotherapy for Asthma: Metanalysis of Randomized Controlled Trials
- I.. Introduction
- II.. Methods
- III.. Results
- IV.. Discussion
- References
- 14.. Noninjective Immunotherapy: Present Knowledge and Experimental Evidence
- I.. General Aspects
- II.. Experimental Evidence
- III.. Clinical Indications
- IV.. Practical Aspects of NIIT
- V.. Conclusions
- References
- 15.. Pediatric Issues in Immunotherapy
- I.. Introduction
- II.. Advantages of Immunotherapy in Children
- III.. Points to Be Considered When Using Immunotherapy in Children
- IV.. Indications for Immunotherapy in Children
- V.. Contraindications for Immunotherapy in Children
- VI.. Summary
- References
- 16.. International Recommendations
- I.. Introduction
- II.. Indications for Immunotherapy
- III.. Contraindications
- IV.. Discontinuation of Immunotherapy
- V.. Monitoring
- VI.. Practicals
- References
- New Forms of Specific Immunotherapy
- 17.. Peptide-Mediated Immunomodulation as Therapy for Allergic Disorders
- I.. Introduction
- II.. Involvement and Activation of CD4[superscript +] T-Cell Subsets in Allergy
- III.. Traditional Immunotherapy
- IV.. Peptide-Mediated Immunomodulation In Vitro
- V.. Peptide-Mediated Modulation of In Vivo Immune Responses
- VI.. Concluding Remarks
- References
- 18.. Potential of Recombinant Allergens as Immunotherapeutic Agents for Allergy and Asthma
- I.. Why Immunotherapy?
- II.. Recombinant Allergens: The Nuts and Bolts
- III.. Rationale for Allergen Immunotherapy for Asthma
- IV.. Effectiveness of Immunotherapy
- V.. Molecular and Cellular Mechanisms of Immunotherapy
- VI.. Allergen Immunotherapy for Asthma
- VII.. Immunotherapy Using Recombinant Allergens
- VIII.. Immunotherapy with Recombinant Allergens and Cytokines
- IX.. Development of Vaccines Against Allergies and Asthma
- X.. Concluding Remarks
- References
- 19.. Molecular Characterization of Allergens, Their B-Cell Epitopes and Allergen-Specific Antibodies for Allergy Prevention and Treatment
- I.. Introduction
- II.. Requirements for Specific Therapy of Type I Allergy Using Recombinant Allergens and Epitopes
- III.. Model: Allergen-Specific and Patient-Tailored Therapy
- IV.. Immunoglobulin E-Binding Haptens for Passive Therapy: Saturation of Effector Cell-Bound IgE
- V.. Immunoglobulin E-Binding Haptens for the Induction of Blocking Antibodies by Active Immunotherapy
- VI.. Nonanaphylactic Modifications and Derivatives of Major Allergens Produced by Recombinant DNA Technology for Active Immunotherapy
- VII.. Allergen-Specific Antibodies and Antibody Fragments for Passive Therapy in the Allergic Effector Organs
- VIII.. Summary
- References
- 20.. Tolerogenic Peptides: Clinical Experience in Allergy
- I.. Introduction
- II.. Experience in Perennial Allergy
- III.. Experience in Seasonal Allergy
- IV.. Anaphylactic Syndromes
- V.. Safety of Peptide Therapy
- References
- 21.. Manipulation of the Idiotypic Network: An Alternative Approach to Treat Allergic Asthma?
- I.. Introduction
- II.. Idiotypic Network
- III.. Role of the Idiotypic Network in Physiopathology of Diseases
- IV.. Manipulating Immune Response with Idiotypic and Anti-Idiotypic Antibodies
- V.. Concluding Remarks
- References
- 22.. The Use of Allergen-Specific Antibodies for Immunotherapy
- I.. Introduction
- II.. Antibody Idiotypes
- III.. Clinical Application
- IV.. State of the Art
- V.. Open Questions
- VI.. Current Work and Perspectives
- References
- Part 3. Regulation of IgE Inflammation
- Immunoglobulin
- 23.. Anti-Immunoglobulin E Therapy for Asthma
- I.. Introduction
- II.. Importance of Immunoglobulin E in Asthma
- III.. MAbs Against Immunoglobulin E
- IV.. Clinical Efficacy of MAbs Against Immunoglobulin E in Asthma and Rhinitis
- V.. Safety
- VI.. Conclusions
- References
- Immunoglobulin Receptors
- 24.. Expression and Function of the High-Affinity Receptor for Immunoglobulin E in Asthma
- I.. Introduction
- II.. Structure and Regulation of Expression of Fc[varepsilon]RI
- III.. Mechanisms of Fc[varepsilon]RI Signaling
- IV.. Human FcR[beta] Polymorphism and Atopy
- References
- 25.. Factors Modulating Allergen-Induced Histamine Release: Fc-Receptors, Antibodies, and Allergens
- I.. Introduction
- II.. Interaction Between Allergen, IgE, and Fc[varepsilon]RI
- III.. Interference of Factors Outside the Fc[varepsilon]RI-IgE-Allergen Complex
- IV.. How Do IgG Antibodies Modulate Histamine Release?
- V.. Anti-IgE Antibodies
- VI.. Summary
- References
- 26.. Regulation of Immunoglobulin E-Mediated Inflammation by Soluble Fragments of the High-Affinity Immunoglobulin E Receptor
- I.. Introduction
- II.. IgE Structure
- III.. Fc[varepsilon]RI Structure
- IV.. Regulation of IgE Levels and Fc[varepsilon]RI Expression
- V.. Soluble Receptor Fragments
- VI.. Soluble Fc[varepsilon]RI[alpha]-IgG "Immunoadhesin"
- VII.. Structure-Based Design of Inhibitors
- VIII.. Summary and Future Prospects
- References
- 27.. Regulation of Immunoglobulin E Inflammation: Anti-Immunoglobulin E Autoantibodies
- I.. Introduction
- II.. Anti-IgE Autoantibodies
- III.. Mimicry of IgE Epitopes
- IV.. Anti-Idiotypic Antibodies as Epitope Mimicry
- V.. Therapeutic Strategies Based on Anti-IgE Antibodies
- VI.. Conclusion
- References
- Part 4. Non-Immunoglobulin E-Dependent Immunotherapy
- 28.. Non-Immunoglobulin E-Dependent Immunotherapy: Treatment of Asthma with Inhaled Interferon Gamma
- I.. Introduction
- II.. Clinical Trials
- III.. Treatment with IFN-[gamma] in a Murine Model of Allergic Sensitization
- IV.. Summary and Future Directions
- References
- 29.. Role of Interleukin-5 in Eosinophil-Based Diseases
- I.. Introduction
- II.. Biochemical Regulation of IL-5
- III.. Eosinophilic Diseases and IL-5
- IV.. Therapeutic Potential of IL-5 Inhibition
- References
- Part 5. Prevention of Allergic Asthma: is it Possible?
- 30.. Primary Prevention of Atopic Asthma: Prophylactic Strategies Based on Immunomodulation of Host Responses During Childhood
- I.. Introduction
- II.. Regulation of T-Cell Immunity in Experimental Animals to Allergens Presented at Mucosal Surfaces: Pointers to Studies in Humans
- III.. Initiation of Allergen-Specific Antibody Responses in Humans: Prospective Seroepidemiological Studies
- IV.. Allergen-Specific T-Cell Reactivity During the Perinatal Period: In Vitro Lymphoproliferation Studies
- V.. Allergen-Specific Cytokine Responses During Childhood
- VI.. Transplacental T-Cell Priming and the Immunology of Pregnancy
- VII.. Kinetics of Postnatal Maturation of Th1-Associated Immune Functions as a "Risk Factor" for Atopy
- VIII.. Regulation of Neonatal Th1 Immunity: The Key Role of Antigen-Presenting Cells
- IX.. Postnatal Maturation of Adaptive Immune Functions: Evidence of Widespread Developmental Deficiencies During Infancy
- X.. Induction and Expression of Atopic Respiratory Disease: A Working Hypothesis
- XI.. Theoretical Options for Early Intervention
- References
- 31.. Outdoor Air Pollution and Asthma
- I.. Introduction
- II.. Human Exposure Studies
- III.. Exacerbation of Asthma
- IV.. Initiation of Asthma
- V.. Conclusions
- References
- 32.. The Genetic Basis of Allergy and Asthma
- I.. Introduction
- II.. Hereditary Contribution to Asthma
- III.. Environmental Contribution to Asthma
- IV.. Phenotype Definition
- V.. Approaches to Genetic Studies of Asthma
- VI.. Linkage Studies with Candidate Genes
- VII.. Linkage Studies with Genome Screening
- VIII.. Candidate Gene Mutational Analysis
- IX.. Future Applications
- X.. Summary
- References
- 33.. Gene Therapy Strategies for Asthma
- I.. Introduction
- II.. Genetics of Asthma
- III.. Strategies for Gene Transfer in Asthma
- IV.. The Most Severe Asthmatic Patients
- V.. Conclusion
- References
- Author Index
- Subject Index
